Cited by 60Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Alterations in cholesterol metabolism–related genes in sporadic Alzheimer's disease

Open access
Picard, Cynthia, Julien, Cédric, Frappier, Josée, Miron, Justin, Théroux, Louise, Dea, Doris, Breitner, John C.S., Poirier, Judes·2018·Neurobiology of Aging

Abstract

Genome-wide association studies have identified several cholesterol metabolism-related genes as top risk factors for late-onset Alzheimer's disease (LOAD). We hypothesized that specific genetic variants could act as disease-modifying factors by altering the expression of those genes. Targeted association studies were conducted with available genomic, transcriptomic, proteomic, and histopathological data from 3 independent cohorts: the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Quebec Founder Population (QFP), and the United Kingdom Brain Expression Consortium (UKBEC). First, a total of 273 polymorphisms located in 17 cholesterol metabolism-related loci were screened for associations with cerebrospinal fluid LOAD biomarkers beta amyloid, phosphorylated tau, and tau (from the ADNI) and with amyloid plaque and tangle densities (from the QFP). Top polymorphisms were then contrasted with gene expression levels measured in 134 autopsied healthy brains (from the UKBEC). In the end, only SREBF2 polymorphism rs2269657 showed significant dual associations with LOAD pathological biomarkers and gene expression levels. Furthermore, SREBF2 expression levels measured in LOAD frontal cortices inversely correlated with age at death; suggesting a possible influence on survival rate.

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2018.01.018

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Polymorphisms in the SREBF2 gene (rs2269657) have been reported to be associated with the risk of developing late onset AD, and SREBF2 mRNA was reported to be significantly higher in AD temporal cortex and cerebellum.

    “Polymorphisms in the SREBF2 gene (rs2269657) have been reported to be associated with the risk of developing late onset AD and SREBF2 mRNA was reported to be significantly higher in AD temporal cortex and cerebellum (55).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Picard, C., Julien, C., Frappier, J., Miron, J., Théroux, L., Dea, D., Breitner, J. C. S., & Poirier, J.
Affiliations
Douglas Mental Health University Institute (CA)
Corresponding author
Poirier, Judes
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2018-06
Volume
66
Pages
180.e1-180.e9
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2792472992
Cited by
60
References
7
Citations by year
2026: 1 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 6 · 2021: 13 · 2020: 5 · 2019: 12 · 2018: 5
FWCI
6.04
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (acceptedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense
  • National Institutes of Health (5u01ag024904-10)
  • Canadian Institutes of Health Research
  • National Institute on Aging (U01-AG-024904)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, late-onset Alzheimer's disease, cholesterol metabolism, SREBF2, genetic polymorphism, gene expression, cerebrospinal fluid biomarkers, amyloid-beta, phosphorylated tau, amyloid plaques, neurofibrillary tangles, age at death, frontal cortex
MeSH terms
Alzheimer Disease, Cholesterol, Frontal Lobe, Humans, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Gene Expression, Amyloid beta-Peptides, tau Proteins, Sterol Regulatory Element Binding Protein 2, Genome-Wide Association Study, Genetic Loci, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review